GE Healthcare
GE Healthcare, a prominent player in the global medical technologies and digital solutions sector, is deeply dedicated to improving patient outcomes and transforming healthcare delivery. Founded in 1892 (as part of General Electric) and headquartered in Chicago, Illinois, the company operates in over 140 countries. In nuclear medicine, GE Healthcare is known for its advanced molecular imaging systems and radiopharmaceuticals, providing creative solutions for both diagnostics and treatments. The company’s core offerings include cutting-edge SPECT/CT and PET/CT scanners, alongside AI-enabled diagnostic solutions that support hospitals and research centers. A key focus is on advancing its nuclear medicine portfolio with systems like the Discovery NM 750i SPECT/CT, which features enhanced image resolution, and integrating AI-powered image analysis tools to enable more accurate diagnostics and efficient clinical operations. Through its Pharma Services, GE HealthCare collaborates with innovators to accelerate therapeutic research, driving advancements in precision medicine.
Latest Market Research Report on Nuclear Medicine Download PDF Brochure Now
Cardinal Health
Cardinal Health is a globally recognized provider of healthcare services and products, established in 1971 and based in Dublin, Ohio. The company plays a crucial role in the nuclear medicine industry by specializing in radiopharmaceutical distribution, nuclear pharmacy services, and theranostic solutions. Cardinal Health holds a significant competitive advantage and large market share, particularly in the U.S., due to its extensive nuclear pharmacy network and highly reliable distribution system. This robust infrastructure ensures the consistent availability of essential isotopes and services to hospitals, clinics, and research institutions nationwide. The company is committed to quality, compliance, and patient safety, offering integrated technologies and expert guidance to help healthcare providers streamline complex daily workflows. By focusing on supply chain innovation and patient support programs, Cardinal Health strengthens global healthcare delivery and its position as a market leader in nuclear medicine.
Curium Pharma
Curium is globally recognized as the world’s leading nuclear medicine company, dedicated to advancing the field through innovation and exceptional service. With over 100 years of combined experience in its heritage, Curium maintains a commitment to quality and providing exceptional outcomes to patients across over 60 countries. The company specializes in radiopharmaceuticals, continually expanding its diverse product portfolio of advanced diagnostic and therapeutic agents. Curium is known for its global reach and recent strategic acquisitions, such as IASON and Eczacıbaşı-Monrol, which have significantly expanded its geographical footprints and enhanced its PET and SPECT infrastructure. Through a pioneering approach, Curium works to ensure outstanding service reliability and drive the nuclear medicine industry forward by facilitating the development of cutting-edge radionuclides and radiopharmaceuticals for patient care.
Lantheus Holdings
Lantheus Holdings, Inc. is a pharmaceutical manufacturing company incorporated in 1956, specializing in Precision diagnostics, Targeted Therapeutics, and Radiopharmaceutical oncology solutions. As a parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., the firm provides innovative diagnostics, targeted therapeutics, and Artificial Intelligence (AI) solutions to the healthcare sector. A major highlight is the launch of PYLARIFY (F-18 PSMA-1007), the first commercially available PSMA PET imaging agent for prostate cancer in the US. Lantheus actively invests in research on next-generation radiopharmaceuticals and theranostics, forging strategic agreements with partners like Perspective Therapeutics for clinical-stage alpha therapies for neuroendocrine tumors. Lantheus’ focus on developing novel imaging agents and targeted therapeutics secures its role as a key leader in precision medicine.
Siemens Healthineers
Siemens Healthineers is a global leader in medical technology and healthcare solutions, established in 1847 and headquartered in Germany. The company is committed to improving patient care and advancing clinical outcomes worldwide through its core offerings in diagnostic imaging systems and clinical workflow solutions. In nuclear medicine, Siemens Healthineers provides advanced imaging systems, including PET/CT and SPECT/CT scanners, as well as nuclear cardiology solutions and AI-enabled diagnostic tools. The company is a pioneer in medical technology, offering products that boost diagnostic potential and enhance patient outcomes. Recent advancements include the Biograph Vision Quadra PET/CT scanner, which offers improved image quality and faster scan times. By focusing on hybrid imaging technologies and digital health innovations, Siemens Healthineers enhances diagnostic accuracy, workflow efficiency, and patient safety in nuclear medicine procedures.
Bayer AG
Bayer AG is a renowned German multinational pharmaceutical and life sciences company, founded in 1863 and headquartered in Leverkusen, Germany. Bayer is recognized globally for its strong focus on oncology, where it actively develops and provides targeted radiopharmaceuticals to improve cancer treatment options. The company leverages nuclear medicine to bridge the gap between precise diagnostics and effective therapies. Bayer is involved in expanding its radiotherapy portfolio for oncology, exemplified by strategic moves such as signing a supply agreement with Ionetix Corporation for the therapeutic radioisotope actinium-225 (Ac-225). Through internal research and external partnerships, Bayer is committed to driving advancements in therapeutic nuclear medicine, particularly the development of targeted alpha therapies for patients with cancer.
Novartis (Advanced Accelerator Applications – AAA)
Novartis, a major pharmaceutical and diagnostics industry giant headquartered in Switzerland, holds a leading position in therapeutic nuclear medicine following its acquisition of Advanced Accelerator Applications (AAA). Novartis excels in targeted radioligand therapies (RLTs), driven by its innovative portfolio that includes products like Lutathera® and Pluvicto™, both used in oncology treatment. The company’s focus is on developing innovative medicines and providing advanced diagnostic solutions, with Pluvicto specifically targeting prostate cancer. Novartis achieved a significant milestone with the FDA’s approval for Pluvicto production at its Milburn facility, reflecting a strategic response to the growing global demand for advanced therapeutic solutions. Its extensive R&D capabilities and commercial reach allow Novartis to maintain dominance and leadership in the rapidly expanding therapeutic nuclear medicine segment.
Jubilant Radiopharma
Jubilant Radiopharma, a global leader in radiopharmaceuticals and part of Jubilant Pharma Limited, focuses on the development, manufacturing, commercialization, and distribution of high-quality diagnostic and therapeutic agents. Established in 2019, the company operates one of the largest nuclear medicine pharmacy networks in the U.S., combining the clinical expertise of a global manufacturer with wide-reaching distribution capabilities. Jubilant Radiopharma’s services encompass Nuclear Medicine, Radiopharmacy, and Cardiac PET solutions. The company is committed to reliable supply chains and quality products, supporting customers today while advancing the practice of nuclear medicine for the future. Strategic collaborations, such as the agreement with Evergreen Theragnostics, further solidify its role in ensuring that healthcare providers can deliver accurate diagnostics and effective treatments.
NorthStar Medical Radioisotopes
NorthStar Medical Radioisotopes is a leading U.S.-based provider of therapeutic and diagnostic radioisotopes, founded in 2006. Dedicated to advancing nuclear medicine and improving patient outcomes, the company specializes in the development, production, and reliable supply of high-quality radioisotopes for clinical and research applications. NorthStar focuses on critical isotopes, offering therapeutic radioisotopes and comprehensive contract development and manufacturing (CDMO) services. The company is known for innovating in the radiopharmaceutical supply chain and ensuring reliable access to critical materials, such as its exclusive deal with GE Healthcare for the manufacturing and distribution of iodine-123 (I-123) capsules in the U.S. NorthStar’s continuous efforts in commercial-scale isotope production and regulatory compliance are essential for supporting global growth in nuclear medicine.
Bracco Imaging S.p.A.
Bracco Imaging S.p.A., part of the Bracco Group, is a major international company specializing in diagnostic imaging and is consistently listed as a key player in the nuclear medicine market. Headquartered in Italy, the company focuses on developing and delivering a comprehensive portfolio of contrast agents and molecular imaging solutions, including various radiopharmaceuticals. Bracco Imaging plays a vital role in diagnostic applications within nuclear medicine, contributing to the detection, staging, and monitoring of a wide array of diseases. Their products support advanced imaging techniques like SPECT and PET. By providing essential diagnostic tools and solutions, Bracco Imaging reinforces its position in the market, ensuring healthcare providers have the necessary resources to perform accurate and informed diagnoses.
Latest Market Research Report on Nuclear Medicine Download PDF Brochure Now